Mikhail Blagosklonny is an oncologist who is responsible for over 170 research articles on the subject of cancer and aging. This includes many articles detailing research into aging and the potential use of rapamycin. He received certification as both a Doctor of Medicine and a Doctor of Philosophy from the First Pavlov State Medical University of St. Peterburg in Russia. He went on to work at the New York Medical College in Valhalla New York. Afterwards he worked as a senior scientist for the Ordway Research Institute in Albany New York. Blagosklonny continued working for the Ordway Research Institute until 2009 on ImpactJournals.com, at which point he became the professor of oncology at Roswell Park Cancer Institute in Buffalo New York as of April 15th.
At Roswell Park Cancer Institute, Blagosklonny has undertaken a lot of research and has produced articles on tandfonline.com such as “Rejuvenating immunity: “anti-aging drug today” eight years later” detailing the drug Everolimus and its effect on immunity in elderly adults, as well as discussing when human again will end as the derivative of medical research such as his.
Mikhail Blagosklonny has formulated a theory involving targets of rapamycin (TOR). He hypothesizes that aging may not be an accumulation of molecular damage, but may instead be caused by cell hyperfunction, and proposes using a drug called rapamycin as a possible treatment for life extension. Blagosklonny is the editor-in-chief for multiple journals, including Oncotarget, Aging, and Cell Cycle. He is considered to be one of the most well-known researchers on the forefront of the study of aging.